Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects
Imumune Thrombocytopenia(ITP) Human Mass Balance
About this trial
This is an interventional health services research trial for Imumune Thrombocytopenia(ITP) Human Mass Balance
Eligibility Criteria
Inclusion Criteria: Subjects who have voluntarily participated in the study and signed the informed consent form with good compliance; Healthy male subjects aged 18-40 years (inclusive); Subjects weighing ≥ 50 kg Subjects in good health status Exclusion Criteria: Subjects with a history of gastrointestinal surgery, renal surgery, cholecystectomy and other procedures that in the judgment of the investigator may affect drug absorption or excretion hypersensitivity to the investigational product and its excipients Subjects with diseases affecting the absorption, distribution, metabolism and excretion of oral drugs, Subjects with fear of needles, hemophobia, difficulty collecting venous blood, or special requirements for diet, who cannot comply with uniform diet Subjects who are abnormal with clinical significance for C-reactive protein or positive for coronavirus nucleic acid detection in coronavirus infection screening Subjects who have participated in another clinical trial of other drugs and have received such investigational product within 3 months prior to the first dose Having any other diseases or conditions that may affect the normal performance of the study or the evaluation of the study data, or having other conditions that are not suitable for the study, as judged by investigators
Sites / Locations
- The First Affiliated Hospital of Soochow University
Arms of the Study
Arm 1
Experimental
HMPL-523
HMPL-523 Tablet 300 mg QD7 days followed by a single oral dose of [14C]HMPL-523 suspension